---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004808"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:21:40.055263+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook

## Summary
- Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).
- AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).
- Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.
- Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).
- Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs.

## SEC filing metadata
- accession: 0001171843-25-004808
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/0001171843-25-004808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/f8k_073025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004808
- JSON: https://secwatch.observer/filing/0001171843-25-004808.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.